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Abstract
Identifying single nucleotide polymorphisms (SNPs) in the genes involved in sepsis may help to clarify the pathophysiology
of neonatal sepsis. The aim of this study was to evaluate the relationships between sepsis in pre-term neonates and genes
potentially involved in the response to invasion by infectious agents. The study involved 101 pre-term neonates born
between June 2008 and May 2012 with a diagnosis of microbiologically confirmed sepsis, 98 pre-term neonates with clinical
sepsis and 100 randomly selected, otherwise healthy pre-term neonates born during the study period. During the study, 47
SNPs in 18 candidate genes were genotyped on Guthrie cards using an ABI PRISM 7900 HT Fast real-time and MAssARRAY
for nucleic acids instruments. Genotypes CT and TT of rs1143643 (the IL1b gene) and genotype GG of rs2664349GG (the
MMP-16 gene) were associated with a significantly increased overall risk of developing sepsis (p = 0.03, p = 0.05 and p= 0.03),
whereas genotypes AG of rs4358188 (the BPI gene) and CT of rs1799946 (the DEFb1 gene) were associated with a
significantly reduced risk of developing sepsis (p = 0.05 for both). Among the patients with bacteriologically confirmed
sepsis, only genotype GG of rs2664349 (the MMP-16 gene) showed a significant association with an increased risk (p = 0.02).
Genotypes GG of rs2569190 (the CD14 gene) and AT of rs4073 (the IL8 gene) were associated with a significantly increased
risk of developing severe sepsis (p = 0.05 and p= 0.01). Genotype AG of rs1800629 (the LTA gene) and genotypes CC and CT
of rs1341023 (the BPI gene) were associated with a significantly increased risk of developing Gram-negative sepsis (p = 0.04,
p = 0.04 and p= 0.03). These results show that genetic variability seems to play a role in sepsis in pre-term neonates by
influencing susceptibility to and the severity of the disease, as well as the risk of having disease due to specific pathogens.
Citation: Esposito S, Zampiero A, Pugni L, Tabano S, Pelucchi C, et al. (2014) Genetic Polymorphisms and Sepsis in Premature Neonates. PLoS ONE 9(7): e101248.
doi:10.1371/journal.pone.0101248
Editor: Stefan Bereswill, Charite´-University Medicine Berlin, Germany
Received April 18, 2014; Accepted June 4, 2014; Published July 7, 2014
Copyright:  2014 Esposito et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: Italian Ministry of Health (Bando Giovani Ricercatori 2009). The funder had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: Co-author and corresponding author Susanna Esposito is a PLOS ONE Editorial Board Member but this does not alter the authors’
adherence to PLOS ONE Editorial policies and criteria.
* Email: susanna.esposito@unimi.it
Introduction
Despite significant advances in supportive care, neonatal sepsis
continues to be a major cause of morbidity and mortality,
particularly among premature infants. It occurs in 1/1,000 full-
term and 4/1,000 premature live births, and mortality rates can
reach values up to 20% in some settings and among very low-
birth-weight (VLBW) infants [1–3].
Susceptibility to, and the severity and outcome of sepsis depend
on various factors, including environmental exposure, host
immune status and inflammatory responses. Over the last few
years, it has been shown that these interacting factors can be
modified by variations in gene function or expression that can lead
to unexpected individual responses to infection [4–6]. Most of the
research in this regard has concentrated on the potential
association between such responses and host genetic variability
in the regulatory and coding region of genes for components of
innate and adaptive immunity in adults and older children, but
rarely infants [7].
There are therefore few data concerning the effects of genetic
variations on the risk of developing, severity and outcome of early-
and late-onset sepsis in neonates, although some reports suggest
that they may be related [8–10].
However, a more rigorous evaluation of the possible association
between genetic variations and neonatal sepsis is particularly
important because of newborn infants have an immature immune
system, and studies of their innate and adaptive responses have
demonstrated that some aspects of innate immunity to bacterial
infection are impaired, particularly in VLBW infants [11,12]. This
per se may predispose to more frequent and/or more severe sepsis.
Identifying genetic variations in the genes involved in bacteria-
induced cell responses and those involved in the pathogenesis of
sepsis may help to clarify the pathophysiology of sepsis in this
group of high-risk patients, and this could lead to the development
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of new diagnostic tools, improved specific therapeutic measures,
and the more accurate prediction of patient outcomes.
The aim of this study was to evaluate the relationships between
sepsis in pre-term neonates and 47 genetic variants in 18 genes
potentially involved in the response to invasion by infectious
agents.
Methods
Study design
This retrospective study involved pre-term infants (,37 weeks’
gestation) admitted to the Neonatal Intensive Care Unit of the
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milan, Italy, between June 2008 and May 2012. The study was
approved by the Ethics Committee of the Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico. Moreover, two of us (LP
and BG) informed parents or legal guardian of the study as well as
obtained written informed consent for the use of clinical data and
blood samples of each child who could be enrolled before the study
was begun.
Three groups of pre-term infants were enrolled. The first group
consisted of 101 pre-term neonates with culture-proven sepsis (i.e.
with signs and symptoms of clinical sepsis associated with at least
one blood culture that was positive for a bacterial pathogen) Blood
cultures positive for following microorganisms generally consid-
ered to be contaminants, including Corynebacterium spp., Propioni-
bacterium spp., and Penicillium spp., were excluded from analysis.
The diagnosis of sepsis due to coagulase-negative Staphylococcus
(CoNS) was based on the criteria of the Vermont Oxford Network
Database [13] and required clinical signs of sepsis, two blood
culture positive for CoNS and intravenous antibacterial therapy
for at least 5 days after performing blood culture, or until death.
Whenever CoNS and another pathogen were identified in the
same blood culture, only the other pathogen was considered the
pathogen. The second consisted of 100 pre-term neonates with
signs and symptoms of clinical sepsis but negative blood culture(s)
during the observation period. The neonates in both groups
systematically received antibiotic therapy for $7 days on the basis
of the findings of microbiological sensitivity tests (when available)
or the recommendations of the international guidelines [14]. The
third group consisted of 100 pre-term neonates who did not have
any respiratory problems, never had a positive blood culture, and
never received antibiotic therapy during hospitalisation. The
neonates in each group were randomly selected on the basis of a
computer-generated randomisation list from among those hospi-
talised in the Neonatal Intensive Care Unit during the study
period. The exclusion criteria were premature infants with birth
defects and those born of pregnancies leading to twins or higher
multiples.
In accordance with the Report on the Expert Meeting on
Neonatal and Paediatric Sepsis (8 June 2010, EMA, London) [15],
clinical sepsis was defined as the presence of at least two clinical
and two laboratory criteria in the previous 24 hours. The clinical
criteria were 1) hyper- or hypothermia or temperature instability; 2)
reduced urinary output or hypotension or mottled skin or
impaired peripheral perfusion; 3) apnea or increased oxygen
requirement or an increased requirement for ventilator support; 4)
episodes of bradycardia or tachycardia or rhythm instability; 5)
feeding intolerance or abdominal distension; 6) lethargy or
hypotonia or irritability; and 7) skin and subcutaneous lesions
such as petechial rash or sclerema. The laboratory criteria were: 1) a
white blood cell (WBC) count of ,4 or .206109 cells/L; 2) an
immature to total neutrophil ratio (I/T) of .0.2; 3) a platelet
count of ,1006109/L; 4) C-reactive protein (CRP) levels of
.15 mg/L or procalcitonin levels of $2 ng/mL; 5) glucose
intolerance when receiving normal amounts of glucose (8–15 g/
kg/day) as expressed by blood glucose values of .180 mg/dL or
hypoglycemia (,40 mg/dL) confirmed at least twice; and 6)
acidosis as characterised by a base excess (BE) of ,210 mmol/L
or lactate levels of .2 mmol/L.
The clinical, laboratory and outcome data were obtained from
the Neonatal Intensive Care Database, whereas genetic evalua-
tions were made using blood extracted from filter Guthrie cards
prepared at birth as part of our routine clinical practice, not used
for the screening of inborn errors of metabolism, and archived in
an envelope.
In accordance with criteria of Goldstein et al. [16], sepsis was
defined severe in the presence of shock, cardiovascular organ
dysfunction or acute respiratory distress syndrome, or two or more
other organ dysfunctions, or death.
Candidate genes
A total of 47 SNPs of 18 candidate genes involved in immune
regulation and the pathogenesis of inflammation and sepsis were
selected for analysis (see Table 1). The genes encode pattern
recognition receptors (CD14, TLR2, and TLR4), intracellular
signalling proteins (IRAK1), pro-inflammatory cytokines (IL1a,
IL1b IL6, and LTA), anti-inflammatory cytokines (IL10),
chemokines (IL8, CXCL10), bactericidal-permeability increasing
protein (BPI), mannose binding lectin-2 (MBL2), beta-defensin1
(DEFb1), matrix metalloproteinase-16 (MMP-16), serpine1, heat
shock protein12A (HSPA12A), and ring finger protein 175
(RNF175). All are located on autosomes except IRAK1, which is
located on the X chromosome. Most of the SNPs are functional
variants or tagging SNPs characterised by the International
HapMap Project: some are known to be involved in the onset,
severity or outcome of sepsis in experimental animals or humans
[4–6], and the others have been previously found to be associated
with an increased risk of developing specific infections or an
abnormal immune response [17–20].
DNA extraction and genotyping
The blood spots on filter paper were cut into 3 mm punches
using a Harris UniCore punch (Whatman, Milan, Italy), and
stored in Eppendorf polypropylene tubes until use. Two punches
were used for the extraction with Masterpure DNA Purification kit
(Epicentre, Madison, FL, USA) according to the manufacturer’s
instructions and using 50 mcL final elution volume after
purification. The DNA extracted was quantified using Picogreen
reagent (Life Technologies, Monza, Italy) and an Infinite M200
PRO fluorimeter (Tecan Italia, Cernusco sul Naviglio, Italy).
Following nucleic acid purification procedures, samples were
stored at 220uC until use.
The SNPs were genotyped using the Custom TaqMan Array
Microfluidic Cards genotyping system on an ABI 7900HT
(Applied Biosystems, Foster City, CA). After PCR amplification,
the alleles were detected by means of end-point analysis using SDS
software and TaqMan Genotyper software (Applied Biosystems).
The genotype data were entered into a Progeny database (Progeny
Software, LLC, South Bend, IN) for the generation of datasets for
analysis. However, because the Taqman genotyping approach
failed in the identification of 11 of the 47 selected SNPs
(rs4859588, rs1800896, rs2569190, rs3921, rs1800871,
rs4986790, rs4859587, rs1800872, rs1143633, rs1800587,
rs8878, respectively) mass spectrometry was used to complete
the study.
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Table 1. Gene and single nucleotide polymorphisms (SNPs).
Gene dbSNP HGVS description Functional consequence Position (bp) Chr Gene location
TLR2 Rs11938228 NG_016229.1:g.21506C.A Intron variant 154621946 4 Intron
Rs4696480 NG_016229.1:g.6686T.A Intron variant 154607126 4 Intron
Rs5743708 NG_016229.1:g.25877G.A Missense 154626317 4 Exon
Rs3804099 NG_016229.1:g.24216T.C Synonymous codon 154624656 4 Exon
Rs3804100 NG_016229.1:g.24969T.C Synonymous codon 154625409 4 Exon
TLR4 Rs1927911 NG_011475.1:g.8595A.G Intron variant 120470054 9 Intron
Rs2149356 NG_011475.1:g.12740T.G Intron variant 120474199 9 Intron
Rs4986790 NG_011475.1:g.13843A.G Missense 120475302 9 Exon
Rs4986791 NG_011475.1:g.14143C.T Missense 120475602 9 Exon
Rs1554973 NG_011475.1:g.19353T.C Transition substitution 120480812 9 Intergenic
CD14 Rs2569190 NG_023178.1:g.5371T.C Intron variant, UTR variant 59 140012916 5 UTR 59
Ring Finger
Protein 175
Rs1585110 NG_016386.1:g.25444G.A Intron variant 154660944 4 Intron
IRAK1 Rs1059703 NG_008387.1:g.11514C.T Intron variant, missense 153278829 X Intron
Rs3027898 NG_008387.1:g.14453G.T Downstream variant,
intron variant
153275890 X Intergenic
IL1a Rs1800587 NG_008850.1:g.5012C.T UTR variant 59 113542960 2 UTR 59
IL1b Rs1143643 NG_008851.1:g.11055G.A Intron variant 113588302 2 Intron
Rs1143633 NG_008851.1:g.8890G.A Intron variant 113590467 2 Intron
Rs1143627 NG_008851.1:g.4970C.T Upstream variant 2KB 113594387 2 Intron
Rs16944 NG_008851.1:g.4490T.C Upstream variant 2KB 113594867 2 Intron
IL6 Rs1800797 NG_011640.1:g.4456A.G Upstream variant 2KB 22766221 7 Intron
Rs1554606 NG_011640.1:g.6942T.G Intron variant,upstream
variant 2KB
22768707 7 Intron
IL8 Rs4073 NG_029889.1:g.4802A.T Upstream variant 2KB 74606024 4 Intergenic
IL10 Rs1800872 NG_012088.1:g.4433A.C Upstream variant 2KB 206946407 1 Intergenic
Rs1800896 NG_012088.1:g.3943A.G Upstream variant 2KB 206946897 1 Intergenic
Rs1800871 NG_012088.1:g.4206T.C Upstream variant 2KB 206946634 1 Intergenic
CXCL-10 Rs8878 NM_001565.3:c.*783T.C Intron variant, UTR variant 39 76942300 4 UTR 39
Rs3921 NM_001565.3:c.*140G.C Intron variant, UTR variant 39 76942943 4 UTR 39
Rs4859587 NM_001565.3:c.279-195T.G Intron variant 76943296 4 Intron
Rs4859588 NM_001565.3:c.189-69C.T Intron variant 76943677 4 Intron
LTA Rs1800629 NG_012010.1:g.8156G.A Upstream variant 2KB 31543031 6 Intergenic
Rs1799964 NG_012010.1:g.7433T.C Downstream variant 500B 31542308 6 Intergenic
Rs2229094 NG_012010.1:g.5681T.C Missense 31540556 6 Exon
Rs1041981 NG_012010.1:g.5909C.A Missense 31540784 6 Exon
MBL2 Rs5030737 NG_008196.1:g.5219C.T Missense 54531242 10 Exon
Rs7096206 NG_008196.1:g.4776C.G Upstream variant 2KB 54531685 10 Intron
Rs1800451 NG_008196.1:g.5235G.A Missense 54531226 10 Exon
Rs1800450 NG_008196.1:g.5226G.A Missense 54531235 10 Exon
BPI Rs4358188 NM_001725.2:c.646G.A Missense 36946848 20 Exon
Rs1341023 NM_001725.2:c.47C.T Missense 36932660 20 Exon
Rs5743507 NM_001725.2:c.546G.C Synonymous codon 36939052 20 Exon
Rs2232578 NM_004139.3:c.-205A.G Upstream variant 2KB 36974715 20 Intergenic
Serpin- a1 Rs7242 NG_013213.1:g.16067T.G UTR variant 39 100781445 7 UTR 39
DEF-b1 Rs11362 NM_005218.3:c.-20G.A UTR variant 59 6735399 8 UTR 59
Rs1799946 NM_005218.3:c.-52G.A UTR variant 59 6735431 8 UTR 59
Rs2741136 NM_005218.3:c.-1817T.C Upstream variant 2KB 6737196 8 Intergenic
MMP-16 Rs2664349 NM_005941.4:c.1084-2311C.T Intron variant 89089282 8 Intron
HSPA-12A Rs740598 NT_030059.13:g.69311363G.A Intron variant 118506899 10 Intron
Bp =base pairs; chr: chromosome; HGVS: Human Genome Variation Society. The position reflects the distance from the short-arm telomere.
doi:10.1371/journal.pone.0101248.t001
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Mass spectrometry
The PCR and extension primers were designed using the Assay
Design suite, version 1.0 (Sequenom, Inc., San Diego, CA, USA),
and simultaneously detected 11 SNPs in a multiplex amplification
reaction. Between 10 and 30 ng of genomic DNA were amplified
by PCR by means of 45 2-minute cycles (95uC for 30 s, 56uC for
30 s, and 72uC for 60 s), followed by 72uC for 5 min, and finally
4uC. The final concentration of each PCR primer was 0.1 mcM
and the final reaction volume was 5 mcL. Subsequently, the excess
dNTPs of the PCR products were removed by means of treatment
with 0.5 U shrimp alkaline phosphatase at 37uC for 40 min and
85uC for 5 min. Single-base extensions were performed in
accordance with the manufacturer’s instructions: 94uC for 30 s
[94uC for 5 s, (52uC for 5 s, 80uC for 5 s) for 5 cycles] for 40
cycles, 72uC for 3 min, and then 4uC. After desalting, the reaction
products were spotted for detection in a mass spectrometer
(Sequenom’s MassARRAY), and the data were analysed using
Typer version 4.0 software (Sequenom).
Statistical analysis
Genotype frequencies were calculated by means of direct
counting. In order to investigate Hardy-Weinberg equilibrium
(HWE), we compared the expected and observed numbers of
different genotypes, and assessed potential deviations using the chi-
squared test or likelihood ratio as appropriate. Univariate odds
ratios (OR) and their 95% confidence intervals (CI) were
calculated in order to measure the associations between selected
SNPs and: 1) susceptibility to sepsis by comparing all children with
sepsis (regardless of bacteriological confirmation) and controls; 2)
susceptibility to bacteriologically confirmed sepsis; 3) susceptibility
to severe sepsis; and 4) susceptibility to Gram-positive sepsis. The
data were controlled for multiple testing using the false discovery
rate method (with the Benjamini-Hochberg procedure). All of the
statistical analyses were made using SAS software, version 9.2
(Cary, NC, USA).
Results
During the study period, the parents of two premature neonates
in the group with clinical sepsis and a negative blood culture
withdrew their authorisation to use their children’s blood and
clinical data. Consequently, the results refer to 101 children with
microbiologically confirmed sepsis, 98 patients with clinical sepsis
and no positive blood culture, and 100 controls. Table 2 shows the
demographic and clinical characteristics of the three groups, which
were perfectly comparable in terms of gestational age, birth
weight, gender, ethnicity and cesarean delivery. The neonates with
microbiologically confirmed or clinical sepsis required mechanical
ventilation significantly more frequently (p,0.05) and had a
significantly worse outcome (p,0.05) than the controls, thus
confirming the importance of sepsis in conditioning the final
outcome. However, there was no difference in these variable
between the two sepsis groups. The children with microbiological
or clinical sepsis had late-onset sepsis (.72 hours) occurring at an
average age of respectively 24 and 26 days.
Table 3 lists the bacterial pathogens identified in the premature
neonates with a positive blood culture. Gram-positive organisms
(mainly CoNS) were cultured in 67.3% of cases, and Gram-
negative rods (mainly Escherichia coli) were identified in the
remaining 32.7%.
All of the examined SNPs were present in the study population.
Table 4 shows the SNPs with significantly different genotype
frequencies between the neonates with bacteriologically confirmed
or clinical sepsis and the controls, and Table 5 those that were
significantly different between the neonates with bacteriologically
confirmed sepsis and controls. Genotypes CT and TT of IL1b-
rs1143643 and GG of MMP-16-rs2664349 were associated with a
significantly increased overall risk of developing sepsis (p = 0.03,
p = 0.05 and p = 0.03), whereas genotypes AG of BPI-rs4358188
and CT of DEFb1-rs1799946 were associated with a significantly
reduced risk (p = 0.05 for both). Only GG genotype of MMP-16-
rs2664349 showed a significant association with an increased risk
of developing bacteriologically confirmed sepsis (p = 0.02).
Table 6 shows the differences in SNP genotype frequencies
between the neonates with severe and non-severe sepsis. GG
genotype of CD14-rs2569190 and AT genotype of IL8-rs4073
were associated with a significantly increased risk of developing
severe sepsis (p = 0.05 and p = 0.01).
Table 7 shows the differences in SNP genotype frequencies
between the neonates with Gram-negative or Gram-positive sepsis.
Genotypes AG of LTA-rs1800629 and CC and CT of BPI-
rs1341023 were associated with a significantly increased risk of
developing Gram-negative sepsis (p = 0.04, p = 0.04 and p = 0.03).
There were no other differences in the studied allele and
genotype frequencies between the neonates with sepsis (overall or
bacteriologically confirmed) and controls, or between those with
severe or non-severe sepsis, or between those with Gram-positive
or Gram-negative sepsis.
Discussion
Identifying genetic variants that can predict human susceptibil-
ity to, and outcomes of sepsis may help to identify patients at
higher risk of death or serious complications who require prompt
and aggressive therapy. This is extremely important in premature
neonates, who are at highest risk of developing poorly controllable
severe bacterial infections for a number of reasons. Susceptibility
to sepsis in our study population was related to SNPs in the IL1b,
MMP-16, BPI, and DEFb1 genes. However, whereas SNPs in the
IL1b and in MMP-16 genes were associated with an increased risk
of sepsis, variations of BPI and DEFb1 seemed to play a protective
role.
The potential role of a genetic alteration in the IL1b gene in
favouring the development of sepsis in premature infants found in
this study is in conflicts with the findings of Abu-Maziad et al. who
did not find any association [8]. This discrepancy may be
explained by differences in the definition of sepsis and its severity,
and in the general characteristics of the enrolled subjects,
including ethnicity. On the other hand, conflicting results
concerning the influence of other IL1b SNPs on the development
and evolution of various infectious diseases have been repeatedly
reported [18,21–24]. Most of the sepsis data have been collected in
studies of rs16944, and Ma et al. [21] and Fang et al. [24] did not
find any correlation between it and susceptibility to sepsis in adults,
whereas Read et al. found that it was associated with increased
survival of in a group of mainly pediatric patients with
meningococcemia [22]. Taken together, these findings indicate
that further studies are needed to clarify whether and which SNPs
of a gene that codes for a factor, IL1b, which plays an important
role in the pathogenesis of sepsis and septic shock, are really
important in conditioning the development and outcome of the
disease [25].
We found that homozygosis for rs2664349-GG haplotype in the
MMP-16 gene is associated with an increased susceptibility to
sepsis in general and to microbiological confirmed sepsis in
particular. This is the first report of the potential effect of a genetic
variation in MMP-16 on sepsis, but the finding seems to be
consistent with recent evidence that MMPs are not only purely
Genetic Polymorphisms and Neonatal Sepsis
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matrix-degrading enzymes as previously thought, but also have
multiple immunomodulation mechanisms [26]. Although the
range of infectious diseases, the organs involved, and the nature
of the resulting tissue damage vary depending on the type of
MMP, all of them play a role in facilitating leukocyte recruitment,
cytokine and chemokine processing, defensin activation, and
matrix remodelling [27]. It has also been found that excess MMP
activity following infection may lead to an immunopathology that
causes host morbidity or mortality and favours pathogen
dissemination or persistence [26]. The possibility that MMP
genetic variations can significantly influence susceptibility to, and
the course and outcome of infectious diseases in humans has been
little studies so far. In the case of sepsis, Chen et al. studied seven
frequent SNPs in the functional regions of the MMP-9 gene, and
found that their genotype distribution and allelic frequencies were
not significantly different between patients with severe sepsis and
controls or between surviving and non-surviving patients with
severe sepsis [28]. We evaluated a SNP of the MMP-16 gene
because, like all MMPs, MMP-16 is a zinc-dependent enzyme and
this trace element is critically important for the normal functioning
of the innate and adaptive immune systems [29]. One consistent
observation made in many gene expression studies is that pediatric
septic shock is characterised by the widespread repression of gene
families that directly participate in zinc homeostasis or directly
depend on it for their normal function [30–34]. Moreover, the
rs2664349 SNP not only seems to influence the pulmonary
expression and function of MMP-16 and the risk of bronchopul-
monary dysplasia in premature infants, but also the activation of
MMP-2 [35], an MMP that plays a central role in monocyte
chemoattraction and, consequently, in the response to infectious
agents.
Among the studied SNPs in the BPI gene, a gene that codifies
for a factor that plays an important antibacterial and antinflam-
matory role [36], only BPI.rs4358188-AG was associated with a
reduced susceptibility to sepsis, whereas BPI rs1341023, rs5743507
and rs2232578 SNPs were apparently not important at this regard.
However, other studies have led to different results. Abu-Maziad
et al. [8] investigated three of the four SNPs evaluated in this study
and found that they had no effect, whereas Michalek et al. [37]
reported a negative association between BPI SNPs and sepsis in
children aged 0–18 years in so far as GG genotype (rs4358188) of
BPI and AG genotype (rs 5743507) were associated with increased
susceptibility to severe sepsis and a negative outcome. Once again,
Table 2. Demographic and clinical characteristics of the study groups.
Characteristic Culture-proven sepsis (n =101) Clinical sepsis (n =98) Controls (n =100)
Median gestational age, weeks (range) 28 (23–36) 28 (24–36) 30 (24–36)
Median birth weight, g (range) 1,040 (470–3,750) 1,000 (360–3,820) 1,310 (420–3,000)
Males (%) 52 (51.5) 53 (54.1) 50 (50.0)
Ethnicity, n (%)
Caucasian 91 (90.1) 86 (87.8) 91 (91.0)
African 4 (4.0) 6 (6.1) 4 (4.0)
Asian 6 (5.9) 6 (6.1) 5 (5.0)
Cesarean delivery, n (%) 60 (59.4) 61 (62.2) 58 (58.0)
Ventilation required, n (%) 87 (86.1)* 71 (72.4)* 9 (9.0)
Negative outcome, n (%) 31 (30.7)* 22 (22.4)* 6 (6.0)
Severe sepsis 21 10 0
Death 10 12 6
*p,0.05 vs controls; no other significant between-group difference.
doi:10.1371/journal.pone.0101248.t002
Table 3. Distribution of pathogens in the blood cultures of 101 neonates with microbiologically-confirmed sepsis.
Pathogen No. (%)
Gram-positive infection 68 (67.3)
Coagulase-negative Staphylococcus 34
Staphylococcus aureus 16
Enterococcus spp. 12
Streptococcus agalactiae 6
Gram-negative infection 31 (30.7)
Escherichia coli 16
Klebsiella species 6
Serratia spp. 5
Pseudomonas spp. 4
doi:10.1371/journal.pone.0101248.t003
Genetic Polymorphisms and Neonatal Sepsis
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differences in the characteristics of the patients and the ethnicity of
the study population could explain the different findings.
On the contrary, the data regarding DEFb1, an antimicrobial
peptide involved in the resistance of epithelial surfaces to microbial
colonisation and the regulation of the release of pro-inflammatory
cytokines and adhesion molecules [38], are quite similar to the
adult data reported by Chen et al. [39]. They studied two of the
DEFb1 SNPs evaluated in this study (rs11362 and rs17999469)
and found that, as in this study, they, together with rs1800972,
were associated with a reduced risk of susceptibility to sepsis and a
reduced risk of severe sepsis, whereas other SNPs were closely
related to an increased risk of disease and its negative evolution.
These findings provide further evidence that DEFb1 is involved in
an immune response that is crucial for the pathophysiology of
severe sepsis.
We found that the severity of sepsis was mainly associated with
CD14 rs2569190-GG and to IL8 rs4073-AT. CD14 is a
component of the lipopolysaccharide receptor molecule and serves
as a central pattern recognition molecule in innate immunity.
Bound to TLR4, it can activate the NF-kB signalling pathway and
initiate an inflammatory response [40]. Our findings are in line
with the results of a recent meta-analysis in which, after evaluating
all of the available data regarding possible associations between
CD14 SNPs and sepsis, it was concluded that CD14 rs2569190 is
not a marker of susceptibility but is more frequent among patients
with severe disease and a poor outcome, and can therefore be
considered a marker of potentially severe sepsis [41].
In addition to CD14 rs2569190-GG, one SNP of the IL8 gene
was also associated with severe sepsis. This is the first demonstra-
tion that an IL8 genetic variation may condition the severity of
sepsis, and conflicts with the finding of Azu-Maziad et al. [8] that
were negative at this regard. However, it is not surprising because
IL8 is a member of the chemokine family that initiates and
amplifies the inflammatory processes that occur in response to a
wide variety of infecting pathogen, and it has been shown that
SNP rs4073-AT of the IL8 gene is associated with increased IL8
production in whole blood stimulated with lipopolysaccharides
[42] and also with severe respiratory infections [43].
Finally, LTA SNPs were associated with an increased risk of
sepsis due to Gram-negative rods. LTA is a mediator of the sepsis
cascade, and it has been previously shown that LTA.rs1800629-
AG genotype is associated with susceptibility to sepsis [44].
Although we did not find this kind of association, the greater
frequency of this SNP in premature neonates with sepsis due to
Gram-negative roads seems to indicate that variations of in the
LTA gene may play a role in conditioning the development of
sepsis, at least when it is potentially caused by specific infectious
agents.
The finding that homogozygotes and heterozygotes for BPI
(rs1341023) seem to be at increased risk of Gram-negative sepsis is
surprising because other SNPs of the same gene seem to play a
protective role. However, the possibility that different variations of
a single gene involved in the regulation of human defences can
lead to opposite results has been widely demonstrated [39].
In conclusion, this study confirms that genetic variability seems
to play a role in susceptibility to, and the severity of neonatal
sepsis, as well as in the risk of sepsis due to specific pathogens.
However, as frequently occurs in the case of genetic studies of the
associations between SNPs and clinical phenotypes, the results
often conflict with previously reported. The main limitations of
such investigations are the small sample sizes, the lack of
simultaneous evaluations of other possibly unknown SNPs that
could influence the final results, and the characteristics of the
control group. However, our findings highlight the potential role
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of various SNPs, whose importance needs to be confirmed by
further studies that should also evaluate the consequences of
mutations on gene expression. If confirmed, the new finding
regarding MMP-16 gene could significantly contribute to a better
understanding of premature infants’ defences against bacterial
invasion and aid the development of more effective therapeutic
measures. Preliminary data suggest that targeting MMPs may be
beneficial in infectious disease, particularly the administration of
direct inhibitors in order to regulate enzyme activity and target the
signalling pathways that up-regulate MMP expression [45,46].
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